Lipocine announces financial results for the first quarter ended march 31, 2022

Salt lake city , may 9, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today announced financial results for the quarter ended march 31, 2022 and provided a corporate update. program highlights tlando™ was approved and granted market exclusivity by the u.s. food and drug administration ("fda") for hypogonadism and our licensee expects commercial launch in second quarter of 2022 lipocine is currently enrolling subjects in a phase 2 proof-of-concept study to evaluate the therapeutic potential of lpcn 1148 for the management of cirrhosis, with enrollment in the study expected to be complete by the end of the third quarter of 2022 lipocine has requested an end of phase 2 meeting to discuss the phase 3 study and confirmatory trial design for lpcn 1144 in non-cirrhotic non-alcoholic steatohepatitis ("nash") an open label extension ("ole") study in non-cirrhotic nash has been completed and topline results are expected in may 2022 board appointments the company appointed jill m.
LPCN Ratings Summary
LPCN Quant Ranking